M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy

Phase 2

Terminated

Conditions: Anatomic Stage III Breast Cancer AJCC v8
HER2/Neu Negative
Anatomic Stage IIB Breast Cancer AJCC v8
Anatomic Stage IIIA Breast Cancer AJCC v8
Inflammatory Breast Carcinoma
Estrogen Receptor Negative
Anatomic Stage IIIB Breast Cancer AJCC v8
Anatomic Stage IIIC Breast Cancer AJCC v8
Progesterone Receptor Negative
Prognostic Stage IIB Breast Cancer AJCC v8

Interventions: Drug: Atorvastatin
Drug: Capecitabine

First Posted Date: 2019-03-13

Last Posted Date: 2024-10-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 6

Registration Number: NCT03872388

Locations: 🇺🇸
Banner - MD Anderson Cancer Center -Northern Colorado, Greeley, Colorado, United States
🇺🇸
Cooper Hospital University Medical Center, Camden, New Jersey, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

and more 2 locations

Low Dose Ipilimumab with Pembrolizumab in Treating Patients with Melanoma That Has Spread to the Brain

Phase 2

Active, not recruiting

Conditions: Clinical Stage IV Cutaneous Melanoma AJCC V8
Metastatic Malignant Neoplasm in the Brain
Metastatic Melanoma
Pathologic Stage IV Cutaneous Melanoma AJCC V8

Interventions: Biological: Ipilimumab
Biological: Pembrolizumab

First Posted Date: 2019-03-13

Last Posted Date: 2024-10-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 26

Registration Number: NCT03873818

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Rapid on Site Evaluation of Pleural Touch Preparations in Diagnosing Malignant Pleural Effusion in Patients Undergoing Pleuroscopy

Not Applicable

Active, not recruiting

Conditions: Malignant Respiratory Tract Neoplasm
Malignant Thoracic Neoplasm
Malignant Neoplasm

Interventions: Procedure: Biopsy
Other: Medical Chart Review
Procedure: Thoracoscopy

First Posted Date: 2019-03-11

Last Posted Date: 2024-11-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 97

Registration Number: NCT03868579

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

and more 1 locations

Fluciclovine F18 PET/CT in Identifying the Origin of Head and Neck Squamous Cell Carcinoma in Patients With Metastatic Cervical Nodal Disease

Early Phase 1

Completed

Conditions: Metastatic Squamous Cell Carcinoma in Cervical Lymph Node
Metastatic Head and Neck Squamous Cell Carcinoma

Interventions: Procedure: Computed Tomography
Radiation: Fluciclovine F18
Procedure: Positron Emission Tomography

First Posted Date: 2019-03-08

Last Posted Date: 2024-03-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 16

Registration Number: NCT03868020

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Fecal Transplant +/- Gut Decontamination in Preventing Acute Graft Versus Host Disease in Patients Given Broad-Spectrum Antibiotics

Phase 2

Withdrawn

Conditions: Graft-versus-host Disease Prevention

Interventions: Procedure: Fecal Microbiota Transplantation
Other: Best Practice
Drug: Nystatin
Drug: Piperacillin-Tazobactam

First Posted Date: 2019-03-05

Last Posted Date: 2020-03-04

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT03862079

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Azacitidine, Venetoclax, and Pevonedistat in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia

Phase 1

Active, not recruiting

Conditions: Acute Myeloid Leukemia
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Chronic Eosinophilic Leukemia, Not Otherwise Specified
Chronic Myelomonocytic Leukemia
Chronic Neutrophilic Leukemia
Essential Thrombocythemia
Myelodysplastic Syndrome
Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
Myeloid Neoplasm

Interventions: Drug: Azacitidine
Drug: Pevonedistat
Drug: Venetoclax

First Posted Date: 2019-03-05

Last Posted Date: 2025-01-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT03862157

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation

Phase 2

Recruiting

Conditions: Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia
Lymphocytic Neoplasm
Lymphoma

Interventions: Procedure: Allogeneic Bone Marrow Transplantation
Biological: Filgrastim-sndz
Drug: Bendamustine
Drug: Fludarabine
Drug: Melphalan
Biological: Inotuzumab Ozogamicin
Procedure: Peripheral Blood Stem Cell Transplantation
Biological: Rituximab
Drug: Tacrolimus

First Posted Date: 2019-02-27

Last Posted Date: 2024-12-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 44

Registration Number: NCT03856216

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Videos and Questionnaires in Assessing Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits

Not Applicable

Active, not recruiting

Conditions: Locally Advanced Malignant Neoplasm
Metastatic Malignant Neoplasm
Advanced Malignant Neoplasm
Malignant Neoplasm
Recurrent Malignant Neoplasm

Interventions: Other: Questionnaire Administration
Other: Video

First Posted Date: 2019-02-27

Last Posted Date: 2024-07-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 125

Registration Number: NCT03856060

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Gender Differences in Switching From Smoking Regular Cigarettes to E-Cigarettes

Not Applicable

Active, not recruiting

Conditions: Cigarette Smoking-Related Carcinoma

Interventions: Drug: Nicotine Replacement
Other: Questionnaire Administration
Device: Electronic Cigarette

First Posted Date: 2019-02-27

Last Posted Date: 2024-12-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 169

Registration Number: NCT03856515

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer

Phase 2

Active, not recruiting

Conditions: Refractory Colorectal Carcinoma
Stage IIIC Colorectal Cancer AJCC v8
Stage IIIB Colorectal Cancer AJCC v8
Stage III Colorectal Cancer AJCC v8
Stage IIIA Colorectal Cancer AJCC v8
Stage IVC Colorectal Cancer AJCC v8
Stage IV Colorectal Cancer AJCC v8
Stage IVA Colorectal Cancer AJCC v8
Stage IVB Colorectal Cancer AJCC v8

Interventions: Other: Laboratory Procedure
Other: Best Practice
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Drug: Regorafenib
Drug: Trifluridine and Tipiracil Hydrochloride

First Posted Date: 2019-02-18

Last Posted Date: 2024-06-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 100

Registration Number: NCT03844620

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Home Terms & Conditions Privacy Policy